copd
becom
major
caus
chronic
morbid
mortal
throughout
world
econom
social
burden
project
increas
come
decad
hospit
acut
exacerb
copd
aecopd
recogn
major
event
natur
histori
copd
due
advers
effect
lung
function
surviv
risk
readmiss
qualiti
life
gener
believ
exacerb
import
target
treatment
prevent
diseas
progress
copd
explor
caus
phenotyp
exacerb
would
identifi
differ
popul
characterist
clinic
outcom
lead
therapeut
consequ
respiratori
infect
recogn
import
trigger
aecopd
also
shown
associ
sever
diseas
howev
littl
known
spectrum
viru
bacteria
respiratori
tract
aecopd
prolong
length
stay
lo
indic
fragil
patient
need
attent
healthi
subject
howev
lack
identifi
predictor
long
lo
although
previou
studi
suggest
correl
lo
respiratori
infect
respiratori
infecti
phenotyp
lo
explor
aecopd
copd
assess
test
cat
good
intern
consist
testretest
reliabl
suitabl
routin
clinic
use
stabl
exacerb
copd
recent
year
howev
inform
correl
cat
respiratori
infecti
phenotyp
well
lo
current
studi
therefor
explor
respiratori
infecti
phenotyp
impact
lo
cat
scale
exacerb
copd
provid
better
understand
diseas
healthcar
plan
patient
cliniciandiagnos
copd
exacerb
screen
accord
strategi
illustr
figur
januari
june
hospit
among
elig
patient
enrol
aecopd
defin
acut
event
character
worsen
respiratori
symptom
dyspnea
sputum
purul
sputum
volum
beyond
normal
daytoday
variat
lead
chang
medic
patient
establish
histori
copd
recruit
postbronchodil
forc
expiratori
volum
second
fev
forc
vital
capac
fvc
ratio
diagnosi
standard
pulmonari
function
test
perform
dri
spiromet
devic
erich
jaeger
gmbh
hoechberg
germani
minut
inhal
salbutamol
ventolin
glaxosmithklin
london
uk
fvc
fev
fev
fvc
ratio
record
addit
patient
abl
understand
complet
cat
independ
exclus
criteria
follow
patient
primari
diagnosi
asthma
bronchiectasi
activ
chronic
respiratori
diseas
requir
treatment
intervent
diagnost
sever
uncontrol
comorbid
patient
mental
disord
condit
associ
immunoinflammatori
respons
patient
receiv
antibiot
corticosteroid
past
week
studi
approv
ethic
committe
anhui
medic
univers
written
inform
consent
obtain
patient
clinic
characterist
patient
record
includ
demograph
inform
smoke
histori
charlson
index
new
global
initi
chronic
obstruct
lung
diseas
gold
stage
system
grade
ad
use
spirometri
exacerb
histori
modifi
british
medic
research
council
andor
cat
result
longterm
oxygen
therapi
cat
scale
lo
tabl
comorbid
includ
hypertens
diabet
mellitu
cerebr
infarct
coronari
arteri
diseas
comorbid
stabl
state
confirm
physician
relat
depart
lo
defin
durat
admiss
discharg
hospit
collect
sampl
pharyng
swab
rotat
five
six
time
allow
remain
second
swab
immedi
immers
ml
viral
preserv
liquid
youkang
technolog
co
beij
peopl
republ
china
store
examin
total
nucleic
acid
dna
rna
extract
purifi
use
mini
kit
qiaamp
minelut
viru
spin
kit
cat
hilden
germani
store
use
pharyng
swab
analyz
consecut
presenc
respiratori
virus
upon
arriv
depart
clinic
laboratori
first
affili
hospit
anhui
medic
univers
analys
includ
influenza
influenza
b
respiratori
syncyti
viru
human
metapneumoviru
parainfluenza
viru
type
coronavirus
cov
cov
cov
enterovirusrhinoviru
adenoviru
human
bocaviru
respiratori
viral
panel
fast
kit
base
multiplex
polymeras
chain
reaction
pcr
flexibl
multianalyt
profil
xmap
xtag
techniqu
luminex
toronto
canada
spontan
sputum
obtain
steril
contain
prior
initi
aecopd
treatment
examin
within
minut
bacteri
analysi
perform
depart
clinic
laboratori
first
affili
hospit
anhui
medic
univers
analys
consist
bacterium
cultur
identif
antibiot
suscept
test
evalu
bacteri
content
sampl
done
follow
normal
procedur
gramstain
sputum
evalu
technician
microbiologist
secret
contain
epithelium
deeper
part
airway
microscop
evalu
consid
suffici
materi
bacteria
associ
epithelium
consid
possibl
pathogen
cultur
dilut
sampl
made
blood
agar
chocol
agar
plate
incub
incub
atmospher
co
overnight
incub
plate
studi
standard
techniqu
pathogen
organ
subject
antibiot
sensit
micro
scan
walk
away
west
sacramento
ca
usa
demograph
clinic
characterist
patient
summar
descript
data
express
mean
standard
deviat
spss
statist
version
use
statist
analysi
group
comparison
test
use
analysi
varianc
test
chisquar
test
pearson
dai
et
al
regress
use
analyz
correl
cat
score
lo
group
compar
use
analysi
varianc
pvalu
consid
signific
statist
analys
januari
june
total
patient
screen
admiss
studi
patient
elig
patient
exclud
two
patient
die
acut
respiratori
failur
figur
categor
patient
four
group
viral
infect
bacteri
infect
coinfect
noninfecti
group
base
pathogen
isol
respiratori
tract
specimen
coinfect
defin
viral
bacteri
infect
differ
among
baselin
characterist
term
sex
distribut
age
bodi
mass
index
packyear
smoke
current
smoke
statu
charlson
index
longterm
oxygen
therapi
tabl
viral
assay
pharyng
swab
show
overal
posit
rate
influenza
viru
frequent
detect
viru
follow
enteroviru
rhinoviru
coronaviru
bocaviru
metapneumoviru
parainfluenza
viru
type
respiratori
syncyti
viru
figur
addit
patient
found
multipl
viral
infect
found
posit
sputum
cultur
follow
bacteria
pseudomona
aeruginosa
acinetobact
baumannii
klebsiella
escherichia
coli
streptococcu
pneumonia
ten
patient
coinfect
found
found
signific
differ
patient
viru
bacteria
infect
term
cat
score
figur
final
also
found
cat
score
posit
correl
lo
aecopd
figur
relationship
respiratori
infecti
phenotyp
fev
new
gold
stage
system
data
fev
shown
tabl
found
statist
signific
differ
fev
among
differ
infecti
aecopd
often
facilit
progress
cours
copd
mainli
due
infect
sever
studi
measur
burden
viral
bacteri
infect
copd
exacerb
howev
littl
inform
avail
respiratori
infecti
phenotyp
caus
agent
exacerb
copd
relationship
lo
cat
scale
present
studi
case
examin
result
show
case
viral
infect
bacteri
infect
seven
figur
detect
rate
respiratori
virus
line
recent
report
two
three
time
higher
use
convent
viral
cultur
method
discrep
could
explain
use
luminex
multiplex
pcr
techniqu
sinc
examin
system
allow
inclus
new
virus
human
metapneumoviru
bocaviru
recent
studi
studi
found
influenza
viru
common
viru
associ
aecopd
consist
result
studi
hong
kong
shown
influenza
detect
viru
exacerb
copd
support
result
influenza
viru
might
caus
agent
exacerb
copd
asia
howev
picornaviru
common
one
studi
western
countri
dispar
distribut
viru
could
relat
geograph
variat
differ
strain
circul
particular
year
time
altern
wider
coverag
influenza
vaccin
western
countri
compar
asia
may
also
contribut
differ
viru
seen
studi
interestingli
studi
also
detect
five
patient
infect
human
metapneumoviru
six
patient
bocaviru
aecopd
first
time
provid
new
insight
understand
etiolog
agent
aecopd
studi
need
explor
less
wellstudi
etiolog
pathogen
aecopd
potenti
bacterium
detect
acut
exacerb
event
demonstr
predomin
p
aeruginosa
baumannii
klebsiella
although
strictli
follow
standard
procedur
collect
specimen
detect
rate
convent
examin
method
rel
lower
modern
cultureindepend
molecular
approach
could
identifi
mani
unrecogn
bacteri
speci
sampl
copd
patient
may
clinic
relev
bacteri
spectrum
gener
agreement
report
previous
peopl
republ
china
differ
western
countri
could
due
region
dispar
bacteri
infect
main
aim
studi
evalu
potenti
relationship
respiratori
tract
infecti
phenotyp
lo
well
cat
scale
lo
wide
use
measur
acut
impact
patient
aecopd
result
show
longest
lo
coinfect
group
shortest
lo
noninfecti
group
consist
previous
report
wilkinson
et
al
demonstr
exacerb
symptom
fev
declin
sever
presenc
bacteria
cold
surrog
viral
infect
cold
bacteri
pathogen
alon
exacerb
associ
human
rhinoviru
haemophilu
influenza
coinfect
exhibit
greater
bacteri
load
inflamm
infect
viral
bacteri
infect
alon
result
show
viral
bacteri
coinfect
would
lead
sever
symptom
longer
lo
patient
recov
invers
increas
chanc
nosocomi
infect
also
social
econom
burden
dramat
therefor
may
conclud
differ
infecti
phenotyp
close
associ
differ
lo
health
statu
aecopd
patient
worth
mention
research
found
cardiovascular
event
pulmonari
embol
blood
stream
infect
may
also
contribut
prolong
stay
patient
copd
howev
check
relev
factor
diseas
associ
prolong
stay
hospit
may
impact
result
take
consider
futur
studi
cat
recent
introduc
patientcomplet
instrument
assess
quantifi
symptom
inflamm
burden
patient
copd
therefor
hypothes
may
correl
respiratori
infecti
phenotyp
cat
explor
yet
sinc
patient
coinfect
exhibit
greater
inflamm
singl
infect
noninfect
infer
coinfect
would
lead
higher
cat
score
support
result
furthermor
also
found
cat
posit
correl
lo
make
cat
use
tool
assess
impact
aecopd
symptom
health
statu
studi
coinfect
group
lower
fev
three
group
howev
statist
signific
differ
agreement
previou
research
wark
et
al
demonstr
differ
acut
fev
without
viru
infect
review
week
follow
admiss
viru
infect
greater
declin
lung
function
compar
without
viru
isol
occur
still
need
investig
furthermor
studi
investig
relationship
potenti
pathogen
bacteria
isol
frequenc
gold
stage
aecopd
found
relationship
stage
bacteria
isol
bear
resembl
research
mortal
import
paramet
predict
prognosi
two
patient
infect
influenza
viru
die
studi
research
show
influenza
viru
pandem
pose
potenti
grave
public
health
threat
high
mortal
rate
observ
infect
peopl
therefor
whether
respiratori
influenza
viral
infect
could
attribut
mortal
copd
exacerb
still
need
investig
respiratori
infecti
phenotyp
associ
lo
sever
symptom
aecopd
furthermor
respiratori
viral
infect
play
import
role
exacerb
copd
cat
may
predictor
longer
lo
coinfect
